Marketing Authorisation for Xonvea in Ireland

Alliance Pharma plc (AIM: APH), the international healthcare group, announces that Xonvea® has gained marketing approval in the Republic of Ireland from the country's medicines regulator, the Health Products Regulatory Authority, for the treatment of nausea and vomiting of pregnancy where conservative management has failed.

Approval in Ireland paves the way for Alliance's first launch of Xonvea outside the UK, where the product was in-licensed from Duchesnay Inc. of Canada in 2015 and launched in October 2018. In Ireland it has been approved for the same indication, nausea and vomiting of pregnancy where conservative management has failed.

In Ireland, as in the UK, nausea and vomiting of pregnancy ("NVP") is the most common medical condition in pregnancy, affecting approximately 46,500 women in Ireland each year* (70%-80% of pregnant women). Research shows that up to 40% of pregnant women report symptoms of nausea and vomiting sufficiently severe to interfere with daily life with at least 1 in 100-150 women hospitalised with the condition in Ireland each year.

It is expected that Xonvea will be launched in Ireland in Q4 2019 and will be marketed directly by Alliance's in-country sales and marketing team.

*Hyperemesis Ireland website

 

For further information:

Alliance Pharma plc

+ 44 (0)1249 466966

Peter Butterfield, Chief Executive Officer

 

Andrew Franklin, Chief Financial Officer

 

www.alliancepharma.co.uk

 

 

Buchanan

+ 44 (0)20 7466 5000

Mark Court / Sophie Wills / Hannah Ratcliff

 

 

 

Numis Securities Limited

+ 44 (0)20 7260 1000

Nominated Adviser: Freddie Barnfield

 

Corporate Broking: James Black

 

 

Investec Bank plc

+ 44 (0)20 7597 5970

Corporate Finance: Daniel Adams / Ed Thomas

 

Corporate Broking: Patrick Robb / Tejas Padalkar

 

 

About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with affiliate offices in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating sales in more than 100 countries.

We currently own or license the rights to more than 90 pharmaceutical and consumer healthcare products, which are managed on a portfolio basis according to their growth potential. Promotional investment is focussed on a small number of brands with significant international or multi-territory reach. The remainder of the portfolio comprises products which are sold in a limited number of local markets and require little or no promotional investment.

Our tried and tested 'Buy and Build' strategy, allows us to benefit both from organic growth opportunities and from enhancing our growth rate through carefully selected acquisitions.

For more information on Alliance, please visit our website:  www.alliancepharmaceuticals.com  

 

About Duchesnay Inc.

Duchesnay Inc. is a specialty pharmaceutical company with a long-standing commitment to women's health. Until recently, the company focused on filling the void in terms of scientific research and education and on developing pharmacological solutions for use during pregnancy and breastfeeding. Today, Duchesnay has broadened its portfolio of products to offer therapeutic options that help to meet the health and quality of life needs of women and their family members at different stages of their lives. For more information about Duchesnay, please visit duchesnay.com

To read more Press Release articles, click here.